Please login to the form below

Not currently logged in
Email:
Password:

Relay Therapeutics strengthens team

Don Bergstorm, Brian Adams and Tom Catinazzo join the biotech

Relay Therapeutics has appointed a new executive vice president, head of research and development in the form of Don Bergstorm.

Bergstorm joins the biotech from Mersana Therapeutics, where he led the advancement of two oncology products.

Prior to this, he was at Sanofi Oncology, where he held a global translational and experimental medicine position.

Relay Therapeutics has also appointed Brian Adams, who joins as its general counsel, bringing more than 15 years of legal and business management experience within the life science sector.

He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

Last but not least, Tom Catinazzo has also joined Relay Therapeutics as its new vice president of finance.

Catinazzo brings over 12 years’ experience in the biotech field having worked at Aileron Therapeutics and Genzyme Corporation supporting both the renal and personalised genetic health division.

Sanjiv Patel, chief executive officer of Relay Therapeutics, said: “We welcome Don, Brian and Tom to the senior team at Relay Therapeutics.

“These seasoned leaders will help us to deliver transformational therapies using our novel integrated experimental and computational platform.

“We will continue to grow and add team members as our portfolio matures towards clinical development, and anticipate a move to our new headquarters in late 2018.”

23rd April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics